This study will be with pediatric patients who have refractory/recurrent solid tumors. They
will receive standard chemotherapy (ICE) and we are investigating if the addition of a new
drug, ODSH, will help to increase the time of their platelet recovery after ICE
chemotherapy.The purpose of this study is to evaluate the safety and tolerability of ODSH in
pediatric patients receiving "ICE" chemotherapy.